Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development
- 2 September 2014
- journal article
- Published by Springer Nature in Medical Oncology
- Vol. 31 (10) , 1-7
Abstract
Esophageal squamous cell carcinoma (ESCC) is a highly malignant tumor which usually is diagnosed in advanced stages due to its asymptomatic course of tumorigenesis. Current therapeutic modalities are not effective enough and the 5-year survival rate of the disease is still very low which prompts the urgent need for finding novel efficient therapeutic methods. In this study, we evaluated ex vivo immune response of ESCC patients against our newly designed chimeric construct consisting of highly immunogenic cancer-testis antigens. After confirming effective expression of the in vitro transcribed chimeric mRNA in ex vivo electroporated dendritic cells (DCs) of the ESCC patients, the patients’ CTLs were primed by DCs and cytotoxicity assay was performed to evaluate how the primed CTLs can recognize and target the chimeric mRNA-loaded cells. The chimeric protein was strongly expressed relative to the housekeeping gene expression in electroporated cells. The cytotoxicity of the CTLs was significantly higher in DCs loaded with chimeric mRNAs compared to mock DCs (p < 0.05) in all of the tested ESCC patients. We are introducing a novel construct that our functional study showed can stimulate and induce an effective immune response in ESCC patients. The designed chimeric mRNA-loaded DCs are capable of priming CTLs effectively and induce cytotoxicity against tumor. Therefore, loading DCs with chimeric epitopes of highly immunogenic antigens, such as cancer-testis antigens, are potentially interesting and effective therapeutic modalities for immunotherapy of ESCC.Keywords
This publication has 29 references indexed in Scilit:
- Trial watchOncoImmunology, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Optimizing Dendritic Cell-Based Immunotherapy: Tackling the Complexity of Different Arms of the Immune SystemMediators of Inflammation, 2012
- MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinomaEuropean Journal of Histochemistry, 2011
- Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine designBMC Cancer, 2010
- Harnessing human dendritic cell subsets for medicineImmunological Reviews, 2010
- Worldwide esophageal cancer collaborationDiseases of the Esophagus, 2009
- Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimensHuman Immunology, 2008
- Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingNature Reviews Immunology, 2007
- Cancer immunotherapy: The past, the present and the futureImmunology & Cell Biology, 2003